Tysabri Surprise Death Casts Grim Doubt On 'Blockbuster'
In November, when their would-be blockbuster drug for multiple sclerosis won FDA approval based on a single year of data, Biogen Idec Inc. and Elan Corp. plc disclosed they had changed the name of the compound from Antegren (which had been used during its development) to the odd-looking and harder-to-pronounce Tysabri.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter